Key facts
- Freya Biosciences’s last known valuation is $65.7M.
- It has raised $66.5M; the latest was Early Stage VC ($20.4M) in Nov 2024.
- Notable investors include Gates Foundation, Denmark's Export and Investment Fund, Sofinnova Partners, CE-Ventures, Indaco Venture Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Freya Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Freya Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Freya Biosciences
Developer of microbial immunotherapies designed to address substantial unmet needs across a range of indications. The company uses a proprietary approach to engineer and provide live microbes that are designed to be safe and effective in humans, enabling doctors to get ensure the development of new treatments for a variety of diseases.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2020
- Employees
- 19
- Website
- freyabiosciences.com/
- Ownership
- Privately Held (backing)
Freya Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Freya Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Freya Biosciences in its N-PORT filings yet. We sweep new filings monthly.